ETF investors in biotechnology stocks may be rattled by the nose-dive of the first heavyweight out of the earnings gate. IShares Nasdaq Biotechnology (IBB), the $10 billion biotech exchange traded fund, has lost 0.8% in the past three trading sessions as Illumina (ILMN) stumbled. Ahead of Celgene's (CELG) and Biogen's (BIIB) reports this week, IBD spoke to Tushar Yadava, an iShares investment strategist, on whether the biotech sector has room to
Wednesday 22 July 2015
Biotech ETFs: 3 Questions For IShares Investing Expert
Otmane El Rhazi from Investor's Business Daily - ETFs RSS.
ETF investors in biotechnology stocks may be rattled by the nose-dive of the first heavyweight out of the earnings gate. IShares Nasdaq Biotechnology (IBB), the $10 billion biotech exchange traded fund, has lost 0.8% in the past three trading sessions as Illumina (ILMN) stumbled. Ahead of Celgene's (CELG) and Biogen's (BIIB) reports this week, IBD spoke to Tushar Yadava, an iShares investment strategist, on whether the biotech sector has room to
ETF investors in biotechnology stocks may be rattled by the nose-dive of the first heavyweight out of the earnings gate. IShares Nasdaq Biotechnology (IBB), the $10 billion biotech exchange traded fund, has lost 0.8% in the past three trading sessions as Illumina (ILMN) stumbled. Ahead of Celgene's (CELG) and Biogen's (BIIB) reports this week, IBD spoke to Tushar Yadava, an iShares investment strategist, on whether the biotech sector has room to
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment